+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Minimal Residual Disease Testing Market by Test Type, Application Areas, End-User Vertical - Global Forecast to 2030- Product Image
Minimal Residual Disease Testing Market by Test Type, Application Areas, End-User Vertical - Global Forecast to 2030- Product Image
Sale

Minimal Residual Disease Testing Market by Test Type, Application Areas, End-User Vertical - Global Forecast to 2030

  • PDF Icon

    Report

  • 185 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5847005
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Minimal Residual Disease (MRD) Testing Market demonstrates robust growth, moving from USD 1.87 billion in 2024 to an anticipated USD 3.54 billion by 2030 at a CAGR of 11.18%.

Importance of Minimal Residual Disease Testing

MRD testing is a pivotal advancement in oncology, providing remarkable sensitivity in detecting residual malignant cells. In the era of precision medicine, MRD testing enhances patient outcomes by tailoring treatment regimens and minimizing overtreatment through precise disease burden assessments. This capability ensures optimized treatment plans, enabling clinicians to effectively employ therapeutic strategies.

The increasing incidence of cancer, coupled with advanced therapeutic options, makes MRD testing essential for monitoring therapy response and relapse risks accurately. Initially prominent in hematologic malignancies, MRD's potential in solid tumors is expanding, promising significant impact across varied cancer types.

Innovative Advancements in MRD Testing

The MRD testing landscape is being transformed by technological innovations, evolving regulations, and clinical paradigm shifts. High-parameter flow cytometry with machine learning analytics enhances reproducibility and throughput. Next-generation sequencing's transition into clinical assays boosts adoption, and digital PCR systems allow absolute quantification with minimal samples, extending MRD's utility in diverse settings.

Lately, MRD's recognition as a therapeutic biomarker by regulatory bodies has influenced reimbursement models. With decentralized testing gaining traction, enhanced evidence and data standards are pivotal in refining MRD solutions and integrating them into clinical care, supporting strategic planning to maintain a competitive advantage.

Impact of U.S. 2025 Tariffs on MRD Supply Chains

In 2025, U.S. tariffs affected MRD supply chains, increasing costs for reagents and diagnostic equipment. This resulted in significant changes across the industry, prompting manufacturers to seek local sourcing and form domestic partnerships to alleviate import-related costs. Adjustments in pricing structures and procurement strategies have reshaped the market landscape, incentivizing local production investments for a more resilient MRD infrastructure.

Key Takeaways from This Report

  • MRD testing's technological advancements are streamlining clinical routines and redefining monitoring protocols.
  • Strategic initiatives like domestic sourcing and local partnerships mitigate tariff impacts, boosting sustainability.
  • Personalized medicine integration and predictive analytics are critical to MRD’s future in precision oncology.

Market Analysis: Segmentation and Growth Insights

The MRD testing market is segmented by test types, application areas, and end-user verticals, each displaying unique growth patterns. For test types:

  • Cytogenetics, including chromosomal microarray and FISH, remain foundational in hematologic malignancies.
  • Flow cytometry, whether multi or single-parameter, leads in high-throughput detection.
  • Next-Generation Sequencing advances with targeted and whole-genome applications.
  • PCR techniques, digital and quantitative, are vital for precise disease quantification.

Application-wise, leukemia, lymphoma, and multiple myeloma are primary adopters, with expanding applications in breast and colorectal cancers. Academic institutions facilitate early technology adoption, while biopharmaceutical companies integrate MRD in clinical trials, contributing to strategic competitive advantages in drug development. Diagnostic laboratories and hospitals are crucial for integrating MRD tests into routine patient care.

Regional Dynamics Influencing MRD Adoption

Regional differences significantly impact MRD testing adoption and integration. In the Americas, structured reimbursement systems and robust reference laboratories facilitate growth. Partnerships between academic and commercial entities enhance data and protocol alignment. In Europe and the Middle East, regulatory variances and emerging diagnostic infrastructures affect accessibility. Efforts to standardize regulations and manufacturing are bridging gaps.

The Asia-Pacific region experiences rapid expansion driven by government-backed oncology programs and improved workflows. Strategic collaborations and public-private partnerships are reshaping the regional MRD landscape, offering opportunities for market entry strategies.

Conclusion

Minimal Residual Disease testing is at a transformative juncture, with innovations and shifting regulations promising to redefine oncology practices. Strategic insights into market drivers and opportunities for competitive advantage will facilitate informed decision-making, paving the way for MRD testing's role in precision care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
3.1. Overview of the Minimal Residual Disease Testing Market's Current Position Significance and Evolution Over Time
3.2. In-Depth Analysis of Consumer Preferences Product Standardization Competitive Dynamics and Regional Regulatory Responses in Minimal Residual Disease Testing Market
3.3. Evaluating the Market Stage With Intellectual Property Landscape And Robust Commercialization Strategies For Minimal Residual Disease Testing
3.4. Comprehensive Market Outlook Future Growth Opportunities Emerging Technological Trends And New Applications In Minimal Residual Disease Testing
4. Market Overview
4.1. Introduction
4.1.1. Comprehensive definition, growth drivers, opportunities, and challenges within the global minimal residual disease testing market
4.1.2. In-depth geographic analysis with cultural, economic, and trade impact on minimal residual disease testing market penetration
4.1.3. Recent innovations, patents, regulatory updates, and strategic industry developments shaping the minimal residual disease testing market
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Growing adoption of liquid biopsy techniques for non-invasive residual disease monitoring
5.1.1. Comprehensive definition and context of liquid biopsy techniques for minimal residual disease testing in oncology
5.1.2. Insightful analysis of market transformation driven by liquid biopsy adoption for residual disease monitoring
5.1.3. Future projections and strategic recommendations for stakeholders embracing liquid biopsy technologies for MRD testing
5.2. Advancements in digital PCR technology enhancing sensitivity of disease detection
5.2.1. In-depth exploration of what advancements in digital PCR technology mean for enhancing disease detection sensitivity
5.2.2. Comprehensive analysis of how advancements in digital PCR technology are reshaping the minimal residual disease testing market landscape
5.2.3. Forward-looking perspective on future developments, potential challenges, and strategic recommendations regarding digital PCR technology in the MRD market
5.3. Rising investment in research focusing on minimal residual disease to support early treatment intervention strategies
5.4. Development of standardized protocols for minimal residual disease assessment across laboratories
5.5. Integration of artificial intelligence tools to improve accuracy and interpretation of minimal residual disease data
5.6. Increasing use of MRD status as a prognostic biomarker in hematologic malignancies
5.7. Rapid growth in the adoption of liquid biopsy techniques for non-invasive monitoring of minimal residual disease
5.8. Focus on cost-effectiveness and accessibility to broaden the reach of minimal residual disease testing in healthcare systems
5.9. Collaborations between diagnostic firms and biopharma to develop companion MRD tests
5.10. Expanding applications of minimal residual disease testing in personalized cancer therapies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Minimal Residual Disease Testing Market, by Test Type
8.1. Introduction
8.2. Cytogenetics
8.2.1. Chromosomal microarray
8.2.2. Fluorescence in situ hybridization (FISH)
8.3. Flow Cytometry
8.3.1. Multi-parameter flow cytometry
8.3.2. Single-parameter flow cytometry
8.4. Next-Generation Sequencing (NGS)
8.4.1. Targeted sequencing
8.4.2. Whole genome sequencing
8.5. Polymerase Chain Reaction (PCR)
8.5.1. Digital PCR
8.5.2. Quantitative PCR
9. Minimal Residual Disease Testing Market, by Application Areas
9.1. Introduction
9.2. Leukemia
9.2.1. Acute Lymphoblastic Leukemia (ALL)
9.2.2. Acute Myeloid Leukemia (AML)
9.2.3. Chronic Lymphocytic Leukemia (CLL)
9.3. Lymphoma
9.3.1. Hodgkin’s lymphoma
9.3.2. Non-Hodgkin’s lymphoma
9.4. Multiple Myeloma
9.5. Solid Tumors
9.5.1. Breast cancer
9.5.2. Colorectal cancer
10. Minimal Residual Disease Testing Market, by End-User Vertical
10.1. Introduction
10.2. Academic & Research Institutes
10.3. Biopharmaceutical Companies
10.4. Diagnostic Laboratories
10.5. Hospitals
11. Americas Minimal Residual Disease Testing Market
11.1. Introduction
11.2. United States
11.3. Canada
11.4. Mexico
11.5. Brazil
11.6. Argentina
12. Europe, Middle East & Africa Minimal Residual Disease Testing Market
12.1. Introduction
12.2. United Kingdom
12.3. Germany
12.4. France
12.5. Russia
12.6. Italy
12.7. Spain
12.8. United Arab Emirates
12.9. Saudi Arabia
12.10. South Africa
12.11. Denmark
12.12. Netherlands
12.13. Qatar
12.14. Finland
12.15. Sweden
12.16. Nigeria
12.17. Egypt
12.18. Turkey
12.19. Israel
12.20. Norway
12.21. Poland
12.22. Switzerland
13. Asia-Pacific Minimal Residual Disease Testing Market
13.1. Introduction
13.2. China
13.3. India
13.4. Japan
13.5. Australia
13.6. South Korea
13.7. Indonesia
13.8. Thailand
13.9. Philippines
13.10. Malaysia
13.11. Singapore
13.12. Vietnam
13.13. Taiwan
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. Adaptive Biotechnologies Corporation
14.3.2. Agilus Diagnostics Ltd.
14.3.3. Amgen Inc.
14.3.3.1. In-depth analysis of Amgen's flagship products and their alignment with evolving patient needs in biotechnology
14.3.3.2. Comprehensive risk and vulnerability assessment with strategic recommendations for Amgen's sustainable market growth
14.3.4. ARUP Laboratories
14.3.5. AstraZeneca PLC
14.3.6. Asuragen Inc. by Bio-Techne Corporation
14.3.7. Bio-Rad Laboratories, Inc.
14.3.7.1. Comprehensive overview of Bio-Rad Laboratories’ strategic market role core strengths and geographic reach
14.3.7.2. In-depth analysis of flagship products and services tailored to molecular diagnostics and MRD testing
14.3.7.3. Critical assessment of risks vulnerabilities and strategic growth opportunities in evolving diagnostic markets
14.3.8. Bristol-Myers Squibb Company
14.3.9. C2I Genomics Inc.
14.3.10. Cergentis B.V.
14.3.11. Exact Sciences Corporation
14.3.12. F. Hoffmann-La Roche Ltd.
14.3.13. Genetron Holdings Limited
14.3.14. GRAIL, LLC by Illumina, Inc.
14.3.15. Guardant Health, Inc.
14.3.16. Integrated DNA Technologies, Inc.
14.3.17. Invivoscribe, Inc.
14.3.18. Kite Pharma, Inc. by Gilead Sciences, Inc.
14.3.19. Laboratory Corporation of America Holdings
14.3.20. Mdxhealth BV
14.3.21. MedGenome Inc
14.3.22. Mission Bio, Inc.
14.3.23. Myriad Genetics, Inc.
14.3.24. Natera Inc.
14.3.25. NeoGenomics Laboratories, Inc.
14.3.26. OPKO Health, Inc.
14.3.27. Quest Diagnostics incorporated
14.3.28. Sysmex Corporation
14.3.29. Veracyte, Inc.
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. MINIMAL RESIDUAL DISEASE TESTING MARKET MULTI-CURRENCY
FIGURE 2. MINIMAL RESIDUAL DISEASE TESTING MARKET MULTI-LANGUAGE
FIGURE 3. MINIMAL RESIDUAL DISEASE TESTING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. MINIMAL RESIDUAL DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHROMOSOMAL MICROARRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTI-PARAMETER FLOW CYTOMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SINGLE-PARAMETER FLOW CYTOMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 19. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2030 (USD MILLION)
TABLE 23. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE MYELOID LEUKEMIA (AML), BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HODGKIN’S LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NON-HODGKIN’S LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 47. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2030 (USD MILLION)
TABLE 48. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 65. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 66. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 67. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 68. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 69. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2030 (USD MILLION)
TABLE 70. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 71. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 72. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 73. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 74. CANADA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
TABLE 75. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 76. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 77. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 78. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 79. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2030 (USD MILLION)
TABLE 80. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 81. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 82. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 83. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 84. MEXICO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 89. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2030 (USD MILLION)
TABLE 90. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
TABLE 126. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 127. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 128. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 129. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 130. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2030 (USD MILLION)
TABLE 131. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 132. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 133. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 134. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 135. GERMANY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
TABLE 136. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 137. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 138. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 139. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 140. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2030 (USD MILLION)
TABLE 141. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 142. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 143. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 144. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 145. FRANCE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
TABLE 146. RUSSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 147. RUSSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 148. RUSSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 149. RUSSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 150. RUSSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2030 (USD MILLION)
TABLE 151. RUSSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
TABLE 156. ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 157. ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 158. ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 159. ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 160. ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2030 (USD MILLION)
TABLE 161. ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 162. ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 163. ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 164. ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 165. ITALY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
TABLE 166. SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 167. SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 168. SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 169. SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 170. SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2030 (USD MILLION)
TABLE 171. SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 172. SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 173. SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 174. SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 175. SPAIN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
TABLE 176. UNITED ARAB EMIRATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 177. UNITED ARAB EMIRATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 178. UNITED ARAB EMIRATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
TABLE 186. SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 187. SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 188. SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 189. SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 190. SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
TABLE 196. SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 197. SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 198. SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
TABLE 206. DENMARK MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 207. DENMARK MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 208. DENMARK MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 209. DENMARK MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 210. DENMARK MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2030 (USD MILLION)
TABLE 211. DENMARK MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 212. DENMARK MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 213. DENMARK MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 214. DENMARK MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 215. DENMARK MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
TABLE 216. NETHERLANDS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 217. NETHERLANDS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 218. NETHERLANDS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 219. NETHERLANDS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 220. NETHERLANDS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
TABLE 226. QATAR MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 227. QATAR MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 228. QATAR MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 229. QATAR MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 230. QATAR MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2030 (USD MILLION)
TABLE 231. QATAR MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 232. QATAR MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 233. QATAR MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 234. QATAR MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 235. QATAR MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
TABLE 236. FINLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 237. FINLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 238. FINLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 239. FINLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 240. FINLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2030 (USD MILLION)
TABLE 241. FINLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 242. FINLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 243. FINLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 244. FINLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 245. FINLAND MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
TABLE 246. SWEDEN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 247. SWEDEN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 250. SWEDEN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2030 (USD MILLION)
TABLE 251. SWEDEN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
TABLE 256. NIGERIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 257. NIGERIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 258. NIGERIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 259. NIGERIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 260. NIGERIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2030 (USD MILLION)
TABLE 261. NIGERIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
TABLE 266. EGYPT MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 267. EGYPT MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 268. EGYPT MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 269. EGYPT MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 270. EGYPT MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2030 (USD MILLION)
TABLE 271. EGYPT MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 272. EGYPT MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 273. EGYPT MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 274. EGYPT MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 275. EGYPT MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
TABLE 276. TURKEY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 277. TURKEY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 278. TURKEY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 279. TURKEY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 280. TURKEY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2030 (USD MILLION)
TABLE 281. TURKEY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 282. TURKEY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
TABLE 283. TURKEY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
TABLE 284. TURKEY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 285. TURKEY MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2030 (USD MILLION)
TABLE 286. ISRAEL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 287. ISRAEL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2030 (USD MILLION)
TABLE 288. ISRAEL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2030 (USD MILLION)
TABLE 289. ISRAEL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2030 (USD MILLION)
TABLE 290. ISRAEL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2030 (USD MILLION)
TABLE 291. ISRAEL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2

Companies Mentioned

The companies profiled in this Minimal Residual Disease Testing market report include:
  • Adaptive Biotechnologies Corporation
  • Agilus Diagnostics Ltd.
  • Amgen Inc.
  • ARUP Laboratories
  • AstraZeneca PLC
  • Asuragen Inc. by Bio-Techne Corporation
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • C2I Genomics Inc.
  • Cergentis B.V.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Genetron Holdings Limited
  • GRAIL, LLC by Illumina, Inc.
  • Guardant Health, Inc.
  • Integrated DNA Technologies, Inc.
  • Invivoscribe, Inc.
  • Kite Pharma, Inc. by Gilead Sciences, Inc.
  • Laboratory Corporation of America Holdings
  • Mdxhealth BV
  • MedGenome Inc
  • Mission Bio, Inc.
  • Myriad Genetics, Inc.
  • Natera Inc.
  • NeoGenomics Laboratories, Inc.
  • OPKO Health, Inc.
  • Quest Diagnostics incorporated
  • Sysmex Corporation
  • Veracyte, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages185
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.08 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.54 Billion
Compound Annual Growth Rate11.1%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis By Offering, Technology, Application Sample - Global Forecast to 2031 - Product Image

Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis By Offering, Technology, Application Sample - Global Forecast to 2031

  • Report
  • 265 Pages
  • Global
From
Minimal Residual Disease Testing Market 2025-2033 - Product Image

Minimal Residual Disease Testing Market 2025-2033

  • Report
  • 138 Pages
  • Global
From
Minimal Residual Disease Testing - Global Strategic Business Report - Product Image

Minimal Residual Disease Testing - Global Strategic Business Report

  • Report
  • 383 Pages
  • Global
From
Minimal Residual Disease Testing Market Report 2025 - Product Image

Minimal Residual Disease Testing Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Minimal Residual Disease Global Market Report 2025 - Product Image

Minimal Residual Disease Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.